ReviewCancer journal (Sudbury, Mass.)
Update on prostate cancer vaccines.
Review in Cancer journal (Sudbury, Mass.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 21 citations in OpenAlex.
- Prostate Cancer Immunotherapy: Time to Move Beyond Checkpoint Inhibitors.ImmunoTargets and therapy · 2025Review
- Article
- Therapeutic metastatic prostate cancer vaccines: lessons learnt from urologic oncology.Central European journal of urology · 2021Review
- Dendritic cell vaccine immunotherapy; the beginning of the end of cancer and COVID-19. A hypothesis.Medical hypotheses · 2021Review
- Personalized peptide vaccines and their relation to other therapies in urological cancer.Nature reviews. Urology · 2017Review
- Surface engineering tumor cells with adjuvant-loaded particles for use as cancer vaccines.Journal of controlled release : official journal of the Controlled Release Society · 2017Article
- Advances on immunotherapy in genitourinary and renal cell carcinoma.Translational cancer research · 2017Article
- Prophylactic Dendritic Cell-Based Vaccines Efficiently Inhibit Metastases in Murine Metastatic Melanoma.PloS one · 2015Article
- Mechanistic target of rapamycin inhibition extends cellular lifespan in dendritic cells by preserving mitochondrial function.Journal of immunology (Baltimore, Md. : 1950) · 2014Article
- Enhancement of the T-cell armamentarium as a cell-based therapy for prostate cancer.Cancer research · 2014Article
- Inhibition of mechanistic target of rapamycin promotes dendritic cell activation and enhances therapeutic autologous vaccination in mice.Journal of immunology (Baltimore, Md. : 1950) · 2012Article
- T cells localized to the androgen-deprived prostate are TH1 and TH17 biased.The Prostate · 2012Article
- [Immunotherapy for metastatic prostate cancer: do we really need this?].Der Urologe. Ausg. A · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
The recent approval of Sipuleucel-T (Dendreon, Seattle, WA) from the Food and Drug Administration for the treatment of men with asymptomatic or minimally symptomatic castrate-resistant prostate cancer was a landmark in cancer immunotherapy, making this the first cancer "vaccine" approved for use in a treatment setting. This approval has led to renewed interest in cancer vaccines and to the recognition that prostate cancer represents an immunologically sensitive disease. At the current time, several vaccine approaches are under clinical investigation. These include viral vectors, antigen-loaded dendritic cells, and DNA vaccines. Each approach has its own set of advantages and disadvantages. This review will introduce the basic technology underlying these different vaccines and briefly discuss completed and ongoing clinical trials. As a great number of prostate cancer vaccines have been investigated in both preclinical and clinical settings, we will focus primarily on vaccines that are currently in clinical trials, as ascertained by a recent inquiry of the clinical trials database, www.clinicaltrials.gov.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.